Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

The EU medicines regulator on Friday rejected Eli Lilly's (LLY.N), opens new tab Alzheimer's drug, saying the treatment's ability to slow cognitive decline was not large enough to outweigh the ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion that does not recommend Eli Lilly (LLY) and Company’s donanemab be granted marketing ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion ...

CHICAGO, March 30 (Reuters) - The highest dose of an experimental drug developed by Eli Lilly (LLY.N), opens new ... Sign up here. No serious adverse events related to the drug were reported.

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency ...

European Medicines Agency advisers said Friday that Eli Lilly’s Alzheimer’s disease treatment should not be approved, once again diverging from their U.S. counterparts. The Committee for ...

We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer ... or dementia who carry one or no copies of the ApoE4 gene.